Replies to post #1832 on Idenix Pharmaceuticals (IDIX)

[DewDiligence]

In evaluating the YMDD issue in HIV/HBV co-infection, it’s important to bear in mind that Lamivudine/Combivir is dying off as a SoC treatment for HIV.

[keitern]

Thanks, there seem to be a few areas where Tyzeka has a chance to become dominant within the HBV market. Pregnant women with HBV, HIV/HBV infected, etc. I suppose this is true for most competing drugs.